{"transactions":[{"id":1466222,"issuer":{"id":5247,"kind":"organization","name":"GYRE THERAPEUTICS, INC."},"owners":[{"id":89367,"kind":"person","name":"USMAN NASSIM","position":1,"cik":"0001206872","reported_name":"USMAN NASSIM","relationship":{"director":true}}],"security":"Stock Option (Right to Buy)","published_at":"2024-07-01T22:00:33.000Z","date":"2024-06-28","kind":"exercise","planned":true,"acquired":false,"shares":3452,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"This option is vested in full."}],"balance_after":278200,"derivative":{"exercise_price":6.93,"expiration_date":"2033-10-31","underlying":"Common Stock","underlying_shares":3452},"source":{"system":"sec-edgar","filing":"0001140361-24-032024","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1124105/000114036124032024/form4.xml","form_type":"4"}},{"id":1466221,"issuer":{"id":5247,"kind":"organization","name":"GYRE THERAPEUTICS, INC."},"owners":[{"id":89367,"kind":"person","name":"USMAN NASSIM","position":1,"cik":"0001206872","reported_name":"USMAN NASSIM","relationship":{"director":true}}],"security":"Common Stock","published_at":"2024-07-01T22:00:33.000Z","date":"2024-06-28","kind":"sale","planned":true,"acquired":false,"shares":3452,"price":12.004,"value":41437.808,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on December 12, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $12.00 to $12.025. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price."}],"balance_after":1636,"source":{"system":"sec-edgar","filing":"0001140361-24-032024","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1124105/000114036124032024/form4.xml","form_type":"4"}},{"id":1466220,"issuer":{"id":5247,"kind":"organization","name":"GYRE THERAPEUTICS, INC."},"owners":[{"id":89367,"kind":"person","name":"USMAN NASSIM","position":1,"cik":"0001206872","reported_name":"USMAN NASSIM","relationship":{"director":true}}],"security":"Common Stock","published_at":"2024-07-01T22:00:33.000Z","date":"2024-06-28","kind":"exercise","planned":true,"acquired":true,"shares":3452,"price":6.93,"value":23922.36,"ownership":{"direct":true},"balance_after":5088,"source":{"system":"sec-edgar","filing":"0001140361-24-032024","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1124105/000114036124032024/form4.xml","form_type":"4"}},{"id":1530800,"issuer":{"id":5247,"kind":"organization","name":"GYRE THERAPEUTICS, INC."},"owners":[{"id":89367,"kind":"person","name":"USMAN NASSIM","position":1,"cik":"0001206872","reported_name":"USMAN NASSIM","relationship":{"director":true}}],"security":"Stock Option (Right to Buy)","published_at":"2024-05-02T22:19:23.000Z","date":"2024-05-01","kind":"exercise","planned":true,"acquired":false,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"This option is vested in full."}],"balance_after":281652,"derivative":{"exercise_price":6.93,"expiration_date":"2033-10-31","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001140361-24-024125","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1124105/000114036124024125/form4.xml","form_type":"4"}},{"id":1530799,"issuer":{"id":5247,"kind":"organization","name":"GYRE THERAPEUTICS, INC."},"owners":[{"id":89367,"kind":"person","name":"USMAN NASSIM","position":1,"cik":"0001206872","reported_name":"USMAN NASSIM","relationship":{"director":true}}],"security":"Common Stock","published_at":"2024-05-02T22:19:23.000Z","date":"2024-05-01","kind":"sale","planned":true,"acquired":false,"shares":100,"price":15.63,"value":1563.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on December 12, 2023."}],"balance_after":1636,"source":{"system":"sec-edgar","filing":"0001140361-24-024125","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1124105/000114036124024125/form4.xml","form_type":"4"}},{"id":1530798,"issuer":{"id":5247,"kind":"organization","name":"GYRE THERAPEUTICS, INC."},"owners":[{"id":89367,"kind":"person","name":"USMAN NASSIM","position":1,"cik":"0001206872","reported_name":"USMAN NASSIM","relationship":{"director":true}}],"security":"Common Stock","published_at":"2024-05-02T22:19:23.000Z","date":"2024-05-01","kind":"sale","planned":true,"acquired":false,"shares":5000,"price":14.9,"value":74500.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on December 12, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $14.50 to $15.32. Upon request by the staff of the Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price."}],"balance_after":1736,"source":{"system":"sec-edgar","filing":"0001140361-24-024125","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1124105/000114036124024125/form4.xml","form_type":"4"}},{"id":1530797,"issuer":{"id":5247,"kind":"organization","name":"GYRE THERAPEUTICS, INC."},"owners":[{"id":89367,"kind":"person","name":"USMAN NASSIM","position":1,"cik":"0001206872","reported_name":"USMAN NASSIM","relationship":{"director":true}}],"security":"Common Stock","published_at":"2024-05-02T22:19:23.000Z","date":"2024-05-01","kind":"sale","planned":true,"acquired":false,"shares":14900,"price":13.86,"value":206514.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on December 12, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $13.50 to $14.44. Upon request by the staff of the U.S. Securities and Exchange Commission (the \"Commission\"), the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price."}],"balance_after":6736,"source":{"system":"sec-edgar","filing":"0001140361-24-024125","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1124105/000114036124024125/form4.xml","form_type":"4"}},{"id":1530796,"issuer":{"id":5247,"kind":"organization","name":"GYRE THERAPEUTICS, INC."},"owners":[{"id":89367,"kind":"person","name":"USMAN NASSIM","position":1,"cik":"0001206872","reported_name":"USMAN NASSIM","relationship":{"director":true}}],"security":"Common Stock","published_at":"2024-05-02T22:19:23.000Z","date":"2024-05-01","kind":"exercise","planned":true,"acquired":true,"shares":20000,"price":6.93,"value":138600.0,"ownership":{"direct":true},"balance_after":21636,"source":{"system":"sec-edgar","filing":"0001140361-24-024125","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1124105/000114036124024125/form4.xml","form_type":"4"}},{"id":1550751,"issuer":{"id":5247,"kind":"organization","name":"GYRE THERAPEUTICS, INC."},"owners":[{"id":89367,"kind":"person","name":"USMAN NASSIM","position":1,"cik":"0001206872","reported_name":"USMAN NASSIM","relationship":{"director":true}}],"security":"Stock Option (Right to Buy)","published_at":"2024-04-03T20:01:48.000Z","date":"2024-04-01","kind":"exercise","planned":true,"acquired":false,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"This option is vested in full."}],"balance_after":301652,"derivative":{"exercise_price":6.93,"expiration_date":"2033-10-31","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001140361-24-017566","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1124105/000114036124017566/form4.xml","form_type":"4"}},{"id":1550750,"issuer":{"id":5247,"kind":"organization","name":"GYRE THERAPEUTICS, INC."},"owners":[{"id":89367,"kind":"person","name":"USMAN NASSIM","position":1,"cik":"0001206872","reported_name":"USMAN NASSIM","relationship":{"director":true}}],"security":"Common Stock","published_at":"2024-04-03T20:01:48.000Z","date":"2024-04-01","kind":"sale","planned":true,"acquired":false,"shares":20000,"price":16.15,"value":323000.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on December 12, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $15.80  to $17.15. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price."}],"balance_after":1636,"source":{"system":"sec-edgar","filing":"0001140361-24-017566","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1124105/000114036124017566/form4.xml","form_type":"4"}},{"id":1550749,"issuer":{"id":5247,"kind":"organization","name":"GYRE THERAPEUTICS, INC."},"owners":[{"id":89367,"kind":"person","name":"USMAN NASSIM","position":1,"cik":"0001206872","reported_name":"USMAN NASSIM","relationship":{"director":true}}],"security":"Common Stock","published_at":"2024-04-03T20:01:48.000Z","date":"2024-04-01","kind":"exercise","planned":true,"acquired":true,"shares":20000,"price":6.93,"value":138600.0,"ownership":{"direct":true},"balance_after":21636,"source":{"system":"sec-edgar","filing":"0001140361-24-017566","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1124105/000114036124017566/form4.xml","form_type":"4"}},{"id":1569939,"issuer":{"id":5247,"kind":"organization","name":"GYRE THERAPEUTICS, INC."},"owners":[{"id":89367,"kind":"person","name":"USMAN NASSIM","position":1,"cik":"0001206872","reported_name":"USMAN NASSIM","relationship":{"director":true}}],"security":"Stock Option (Right to Buy)","published_at":"2024-03-19T20:47:45.000Z","date":"2024-03-15","kind":"exercise","planned":true,"acquired":false,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"This option is vested in full."}],"balance_after":321652,"derivative":{"exercise_price":6.93,"expiration_date":"2033-10-31","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001140361-24-014164","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1124105/000114036124014164/form4.xml","form_type":"4"}},{"id":1569938,"issuer":{"id":5247,"kind":"organization","name":"GYRE THERAPEUTICS, INC."},"owners":[{"id":89367,"kind":"person","name":"USMAN NASSIM","position":1,"cik":"0001206872","reported_name":"USMAN NASSIM","relationship":{"director":true}}],"security":"Common Stock","published_at":"2024-03-19T20:47:45.000Z","date":"2024-03-15","kind":"sale","planned":true,"acquired":false,"shares":20000,"price":17.26,"value":345200.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on December 12, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $16.07 to $18.69. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price."}],"balance_after":1636,"source":{"system":"sec-edgar","filing":"0001140361-24-014164","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1124105/000114036124014164/form4.xml","form_type":"4"}},{"id":1569937,"issuer":{"id":5247,"kind":"organization","name":"GYRE THERAPEUTICS, INC."},"owners":[{"id":89367,"kind":"person","name":"USMAN NASSIM","position":1,"cik":"0001206872","reported_name":"USMAN NASSIM","relationship":{"director":true}}],"security":"Common Stock","published_at":"2024-03-19T20:47:45.000Z","date":"2024-03-15","kind":"exercise","planned":true,"acquired":true,"shares":20000,"price":6.93,"value":138600.0,"ownership":{"direct":true},"balance_after":21636,"source":{"system":"sec-edgar","filing":"0001140361-24-014164","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1124105/000114036124014164/form4.xml","form_type":"4"}},{"id":1752574,"issuer":{"id":5247,"kind":"organization","name":"GYRE THERAPEUTICS, INC."},"owners":[{"id":89367,"kind":"person","name":"USMAN NASSIM","position":1,"cik":"0001206872","reported_name":"USMAN NASSIM","relationship":{"director":true}}],"security":"Stock Option (Right to Buy)","published_at":"2023-11-01T10:15:26.000Z","date":"2023-10-31","kind":"grant","planned":false,"acquired":true,"shares":1866,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"These options vest as to one-third on each of the first, second and third anniversaries of October 31, 2023, subject to the Reporting Person's continued service to the Issuer through each vesting date."}],"balance_after":1866,"derivative":{"exercise_price":6.93,"expiration_date":"2033-10-31","underlying":"Common Stock","underlying_shares":1866},"source":{"system":"sec-edgar","filing":"0001140361-23-050616","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1124105/000114036123050616/form4.xml","form_type":"4"}},{"id":1752573,"issuer":{"id":5247,"kind":"organization","name":"GYRE THERAPEUTICS, INC."},"owners":[{"id":89367,"kind":"person","name":"USMAN NASSIM","position":1,"cik":"0001206872","reported_name":"USMAN NASSIM","relationship":{"director":true}}],"security":"Stock Option (Right to Buy)","published_at":"2023-11-01T10:15:26.000Z","date":"2023-10-31","kind":"grant","planned":false,"acquired":true,"shares":341652,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"These options are vested in full."}],"balance_after":341652,"derivative":{"exercise_price":6.93,"expiration_date":"2033-10-31","underlying":"Common Stock","underlying_shares":341652},"source":{"system":"sec-edgar","filing":"0001140361-23-050616","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1124105/000114036123050616/form4.xml","form_type":"4"}},{"id":1791158,"issuer":{"id":5247,"kind":"organization","name":"GYRE THERAPEUTICS, INC."},"owners":[{"id":89367,"kind":"person","name":"USMAN NASSIM","position":1,"cik":"0001206872","reported_name":"USMAN NASSIM","relationship":{"director":true,"officer":true,"officer_title":"President & CEO"}}],"security":"Series Y Preferred Stock","published_at":"2023-09-01T20:07:09.000Z","date":"2023-08-31","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":1.168,"ownership":{"direct":false,"nature":"By Nassim Usman IRA"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"On June 20, 2023, the Company's board of directors (the \"Board\") declared a dividend of one one-thousandth of a share of Series Y Preferred Stock, par value $0.001 per share (the \"Preferred Stock\"), for each outstanding share of common stock to common stockholders of record at 5:00 p.m. Eastern Time on June 30, 2023, in a transaction exempt from Section 16 under Rule 16a-9. The shares of Preferred Stock were distributed on June 30, 2023. As a result, the Reporting Person received the shares of Preferred Stock set forth above. The Preferred Stock was not convertible into, or exchangeable for, shares of any other class or series of stock or other securities of the Company."},{"field":"shares","element":"transactionShares","label":"F2","text":"On August 31, 2023, the Company filed, as approved by the Board, a certificate of elimination with the Secretary of State of the State of Delaware pursuant to which the outstanding shares of the Preferred Stock were eliminated."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On August 31, 2023, the Company filed, as approved by the Board, a certificate of elimination with the Secretary of State of the State of Delaware pursuant to which the outstanding shares of the Preferred Stock were eliminated."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001140361-23-042367","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1124105/000114036123042367/form4.xml","form_type":"4"}},{"id":1791157,"issuer":{"id":5247,"kind":"organization","name":"GYRE THERAPEUTICS, INC."},"owners":[{"id":89367,"kind":"person","name":"USMAN NASSIM","position":1,"cik":"0001206872","reported_name":"USMAN NASSIM","relationship":{"director":true,"officer":true,"officer_title":"President & CEO"}}],"security":"Series Y Preferred Stock","published_at":"2023-09-01T20:07:09.000Z","date":"2023-08-31","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":8.456,"ownership":{"direct":false,"nature":"By The Usman Family Trust"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"On June 20, 2023, the Company's board of directors (the \"Board\") declared a dividend of one one-thousandth of a share of Series Y Preferred Stock, par value $0.001 per share (the \"Preferred Stock\"), for each outstanding share of common stock to common stockholders of record at 5:00 p.m. Eastern Time on June 30, 2023, in a transaction exempt from Section 16 under Rule 16a-9. The shares of Preferred Stock were distributed on June 30, 2023. As a result, the Reporting Person received the shares of Preferred Stock set forth above. The Preferred Stock was not convertible into, or exchangeable for, shares of any other class or series of stock or other securities of the Company."},{"field":"shares","element":"transactionShares","label":"F2","text":"On August 31, 2023, the Company filed, as approved by the Board, a certificate of elimination with the Secretary of State of the State of Delaware pursuant to which the outstanding shares of the Preferred Stock were eliminated."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On August 31, 2023, the Company filed, as approved by the Board, a certificate of elimination with the Secretary of State of the State of Delaware pursuant to which the outstanding shares of the Preferred Stock were eliminated."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001140361-23-042367","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1124105/000114036123042367/form4.xml","form_type":"4"}},{"id":1791156,"issuer":{"id":5247,"kind":"organization","name":"GYRE THERAPEUTICS, INC."},"owners":[{"id":89367,"kind":"person","name":"USMAN NASSIM","position":1,"cik":"0001206872","reported_name":"USMAN NASSIM","relationship":{"director":true,"officer":true,"officer_title":"President & CEO"}}],"security":"Series Y Preferred Stock","published_at":"2023-09-01T20:07:09.000Z","date":"2023-08-31","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":24.541,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"On June 20, 2023, the Company's board of directors (the \"Board\") declared a dividend of one one-thousandth of a share of Series Y Preferred Stock, par value $0.001 per share (the \"Preferred Stock\"), for each outstanding share of common stock to common stockholders of record at 5:00 p.m. Eastern Time on June 30, 2023, in a transaction exempt from Section 16 under Rule 16a-9. The shares of Preferred Stock were distributed on June 30, 2023. As a result, the Reporting Person received the shares of Preferred Stock set forth above. The Preferred Stock was not convertible into, or exchangeable for, shares of any other class or series of stock or other securities of the Company."},{"field":"shares","element":"transactionShares","label":"F2","text":"On August 31, 2023, the Company filed, as approved by the Board, a certificate of elimination with the Secretary of State of the State of Delaware pursuant to which the outstanding shares of the Preferred Stock were eliminated."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On August 31, 2023, the Company filed, as approved by the Board, a certificate of elimination with the Secretary of State of the State of Delaware pursuant to which the outstanding shares of the Preferred Stock were eliminated."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001140361-23-042367","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1124105/000114036123042367/form4.xml","form_type":"4"}},{"id":2189843,"issuer":{"id":5247,"kind":"organization","name":"GYRE THERAPEUTICS, INC."},"owners":[{"id":89367,"kind":"person","name":"USMAN NASSIM","position":1,"cik":"0001206872","reported_name":"USMAN NASSIM","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2022-08-10T21:19:56.000Z","date":"2022-08-09","kind":"purchase","acquired":true,"shares":3250,"price":0.47,"value":1527.5,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Shares purchased under the Issuer's 2018 Employee Stock Purchase Plan on August 9, 2022."}],"balance_after":24541,"source":{"system":"sec-edgar","filing":"0001209191-22-045256","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1124105/000120919122045256/doc4.xml","form_type":"4"}},{"id":2392352,"issuer":{"id":5247,"kind":"organization","name":"GYRE THERAPEUTICS, INC."},"owners":[{"id":89367,"kind":"person","name":"USMAN NASSIM","position":1,"cik":"0001206872","reported_name":"USMAN NASSIM","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2022-02-17T01:13:34.000Z","date":"2022-02-09","kind":"purchase","acquired":true,"shares":3250,"price":0.46,"value":1495.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Shares purchased under the Issuer's 2018 Employee Stock Purchase Plan on February 9, 2022."}],"balance_after":21291,"source":{"system":"sec-edgar","filing":"0001209191-22-010407","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1124105/000120919122010407/doc4.xml","form_type":"4"}},{"id":2607256,"issuer":{"id":5247,"kind":"organization","name":"GYRE THERAPEUTICS, INC."},"owners":[{"id":89367,"kind":"person","name":"USMAN NASSIM","position":1,"cik":"0001206872","reported_name":"USMAN NASSIM","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2021-08-11T13:15:33.000Z","date":"2021-08-09","kind":"purchase","acquired":true,"shares":867,"price":3.62,"value":3138.54,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Shares purchased under the Issuer's 2018 Employee Stock Purchase Plan on August 9, 2021."}],"balance_after":18041,"source":{"system":"sec-edgar","filing":"0001209191-21-050759","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1124105/000120919121050759/doc4.xml","form_type":"4"}},{"id":2739813,"issuer":{"id":5247,"kind":"organization","name":"GYRE THERAPEUTICS, INC."},"owners":[{"id":89367,"kind":"person","name":"USMAN NASSIM","position":1,"cik":"0001206872","reported_name":"USMAN NASSIM","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2021-04-26T21:39:51.000Z","date":"2021-02-08","kind":"grant","acquired":true,"shares":140000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Award vests and will become exercisable monthly over 48 months, with 25% of the shares vesting on the 12-month anniversary of the date hereof, and the remainder vesting monthly thereafter at the rate of 1/48th of the total number of shares."}],"balance_after":140000,"derivative":{"exercise_price":5.89,"expiration_date":"2031-02-08","underlying":"Common Stock","underlying_shares":140000},"source":{"system":"sec-edgar","filing":"0001209191-21-028358","document":"doc4a.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1124105/000120919121028358/doc4a.xml","form_type":"4/A","original_submission_date":"2021-02-10"}},{"id":2754591,"issuer":{"id":5247,"kind":"organization","name":"GYRE THERAPEUTICS, INC."},"owners":[{"id":89367,"kind":"person","name":"USMAN NASSIM","position":1,"cik":"0001206872","reported_name":"USMAN NASSIM","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2021-04-07T14:55:14.000Z","date":"2021-04-05","kind":"exercise","acquired":false,"shares":5000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The Option vests monthly over a period of four years commencing June 15, 2017."}],"balance_after":259783,"derivative":{"exercise_price":4.63,"expiration_date":"2027-07-11","underlying":"Common Stock","underlying_shares":5000},"source":{"system":"sec-edgar","filing":"0001209191-21-025783","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1124105/000120919121025783/doc4.xml","form_type":"4"}},{"id":2754590,"issuer":{"id":5247,"kind":"organization","name":"GYRE THERAPEUTICS, INC."},"owners":[{"id":89367,"kind":"person","name":"USMAN NASSIM","position":1,"cik":"0001206872","reported_name":"USMAN NASSIM","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2021-04-07T14:55:14.000Z","date":"2021-04-05","kind":"exercise","acquired":true,"shares":5000,"price":4.63,"value":23150.0,"ownership":{"direct":true},"balance_after":17174,"source":{"system":"sec-edgar","filing":"0001209191-21-025783","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1124105/000120919121025783/doc4.xml","form_type":"4"}},{"id":2843662,"issuer":{"id":5247,"kind":"organization","name":"GYRE THERAPEUTICS, INC."},"owners":[{"id":89367,"kind":"person","name":"USMAN NASSIM","position":1,"cik":"0001206872","reported_name":"USMAN NASSIM","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2021-02-23T02:33:49.000Z","date":"2021-02-09","kind":"purchase","acquired":true,"shares":582,"price":4.81,"value":2799.42,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Shares purchased under the Issuer's 2018 Employee Stock Purchase Plan on February 9, 2021."}],"balance_after":12174,"source":{"system":"sec-edgar","filing":"0001209191-21-013037","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1124105/000120919121013037/doc4.xml","form_type":"4"}},{"id":2869699,"issuer":{"id":5247,"kind":"organization","name":"GYRE THERAPEUTICS, INC."},"owners":[{"id":89367,"kind":"person","name":"USMAN NASSIM","position":1,"cik":"0001206872","reported_name":"USMAN NASSIM","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2021-02-10T22:51:52.000Z","date":"2021-02-08","kind":"grant","acquired":true,"shares":140000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Award vests over a four (4) year period on each monthly anniversary commencing February 8, 2021."}],"balance_after":140000,"derivative":{"exercise_price":5.89,"expiration_date":"2031-02-08","underlying":"Common Stock","underlying_shares":140000},"source":{"system":"sec-edgar","filing":"0001209191-21-009355","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1124105/000120919121009355/doc4.xml","form_type":"4"}},{"id":3060566,"issuer":{"id":5247,"kind":"organization","name":"GYRE THERAPEUTICS, INC."},"owners":[{"id":89367,"kind":"person","name":"USMAN NASSIM","position":1,"cik":"0001206872","reported_name":"USMAN NASSIM","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2020-08-12T20:12:20.000Z","date":"2020-08-10","kind":"purchase","acquired":true,"shares":582,"price":4.81,"value":2799.42,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Shares purchased under the Issuer's 2018 Employee Stock Purchase Plan on August 10, 2020."}],"balance_after":11592,"source":{"system":"sec-edgar","filing":"0001209191-20-046348","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1124105/000120919120046348/doc4.xml","form_type":"4"}},{"id":3211460,"issuer":{"id":5247,"kind":"organization","name":"GYRE THERAPEUTICS, INC."},"owners":[{"id":89367,"kind":"person","name":"USMAN NASSIM","position":1,"cik":"0001206872","reported_name":"USMAN NASSIM","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2020-03-13T22:56:58.000Z","date":"2020-03-13","kind":"purchase","acquired":true,"shares":4000,"price":3.9118,"value":15647.2,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents the weighted average purchase price per share. The shares were purchased at prices ranging from $3.87 to $3.92 per share. Full information regarding the number of shares purchased at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer."}],"balance_after":11010,"source":{"system":"sec-edgar","filing":"0001209191-20-019040","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1124105/000120919120019040/doc4.xml","form_type":"4"}},{"id":3277580,"issuer":{"id":5247,"kind":"organization","name":"GYRE THERAPEUTICS, INC."},"owners":[{"id":89367,"kind":"person","name":"USMAN NASSIM","position":1,"cik":"0001206872","reported_name":"USMAN NASSIM","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2020-02-13T01:28:42.000Z","date":"2020-02-10","kind":"grant","acquired":true,"shares":430,"price":6.23,"value":2678.9,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Shares purchased under the Catalyst Biosciences, Inc. 2018 Employee Stock Purchase Plan (\"ESPP\") on February 10, 2020."}],"balance_after":7010,"source":{"system":"sec-edgar","filing":"0001209191-20-009041","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1124105/000120919120009041/doc4.xml","form_type":"4"}},{"id":3301675,"issuer":{"id":5247,"kind":"organization","name":"GYRE THERAPEUTICS, INC."},"owners":[{"id":89367,"kind":"person","name":"USMAN NASSIM","position":1,"cik":"0001206872","reported_name":"USMAN NASSIM","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2020-01-27T19:00:12.000Z","date":"2020-01-23","kind":"grant","acquired":true,"shares":115000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Award vests over a four (4) year period on each monthly anniversary commencing January 23, 2020."}],"balance_after":115000,"derivative":{"exercise_price":6.85,"expiration_date":"2030-01-23","underlying":"Common Stock","underlying_shares":115000},"source":{"system":"sec-edgar","filing":"0001209191-20-004965","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1124105/000120919120004965/doc4.xml","form_type":"4"}},{"id":3441360,"issuer":{"id":5247,"kind":"organization","name":"GYRE THERAPEUTICS, INC."},"owners":[{"id":89367,"kind":"person","name":"USMAN NASSIM","position":1,"cik":"0001206872","reported_name":"USMAN NASSIM","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2019-08-12T20:21:37.000Z","date":"2019-08-12","kind":"grant","acquired":true,"shares":413,"price":6.51,"value":2688.63,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Shares purchased under the Catalyst Biosciences, Inc. 2018 Employee Stock Purchase Plan (\"ESPP\") on August 12, 2019."}],"balance_after":6580,"source":{"system":"sec-edgar","filing":"0001209191-19-045504","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1124105/000120919119045504/doc4.xml","form_type":"4"}},{"id":3515586,"issuer":{"id":5247,"kind":"organization","name":"GYRE THERAPEUTICS, INC."},"owners":[{"id":89367,"kind":"person","name":"USMAN NASSIM","position":1,"cik":"0001206872","reported_name":"USMAN NASSIM","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2019-05-22T18:17:38.000Z","date":"2019-05-20","kind":"exercise","acquired":false,"shares":4400,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The Option vests monthly over a period of four years commencing June 15, 2017."}],"balance_after":264783,"derivative":{"exercise_price":4.63,"expiration_date":"2027-07-11","underlying":"Common Stock","underlying_shares":4400},"source":{"system":"sec-edgar","filing":"0001209191-19-031970","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1124105/000120919119031970/doc4.xml","form_type":"4"}},{"id":3515585,"issuer":{"id":5247,"kind":"organization","name":"GYRE THERAPEUTICS, INC."},"owners":[{"id":89367,"kind":"person","name":"USMAN NASSIM","position":1,"cik":"0001206872","reported_name":"USMAN NASSIM","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2019-05-22T18:17:38.000Z","date":"2019-05-21","kind":"gift","acquired":true,"shares":4400,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By The Usman Family Trust"},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"On May 21, 2019, the reporting person transferred 4,400 directly owned shares of Company common stock to the Usman Family Trust of which the insider and his wife are trustees and beneficiaries."}],"balance_after":8456,"source":{"system":"sec-edgar","filing":"0001209191-19-031970","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1124105/000120919119031970/doc4.xml","form_type":"4"}},{"id":3515584,"issuer":{"id":5247,"kind":"organization","name":"GYRE THERAPEUTICS, INC."},"owners":[{"id":89367,"kind":"person","name":"USMAN NASSIM","position":1,"cik":"0001206872","reported_name":"USMAN NASSIM","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2019-05-22T18:17:38.000Z","date":"2019-05-21","kind":"gift","acquired":false,"shares":4400,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"On May 21, 2019, the reporting person transferred 4,400 directly owned shares of Company common stock to the Usman Family Trust of which the insider and his wife are trustees and beneficiaries."}],"balance_after":6167,"source":{"system":"sec-edgar","filing":"0001209191-19-031970","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1124105/000120919119031970/doc4.xml","form_type":"4"}},{"id":3515583,"issuer":{"id":5247,"kind":"organization","name":"GYRE THERAPEUTICS, INC."},"owners":[{"id":89367,"kind":"person","name":"USMAN NASSIM","position":1,"cik":"0001206872","reported_name":"USMAN NASSIM","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2019-05-22T18:17:38.000Z","date":"2019-05-21","kind":"exercise","acquired":true,"shares":4400,"price":4.63,"value":20372.0,"ownership":{"direct":true},"balance_after":10567,"source":{"system":"sec-edgar","filing":"0001209191-19-031970","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1124105/000120919119031970/doc4.xml","form_type":"4"}},{"id":3660809,"issuer":{"id":5247,"kind":"organization","name":"GYRE THERAPEUTICS, INC."},"owners":[{"id":89367,"kind":"person","name":"USMAN NASSIM","position":1,"cik":"0001206872","reported_name":"USMAN NASSIM","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2019-02-13T22:01:11.000Z","date":"2019-02-11","kind":"grant","acquired":true,"shares":350,"price":7.04,"value":2464.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Shares purchased under the Catalyst Biosciences, Inc. 2018 Employee Stock Purchase Plan (\"ESPP\") on February 11, 2019."}],"balance_after":6167,"source":{"system":"sec-edgar","filing":"0001209191-19-009705","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1124105/000120919119009705/doc4.xml","form_type":"4"}},{"id":3677849,"issuer":{"id":5247,"kind":"organization","name":"GYRE THERAPEUTICS, INC."},"owners":[{"id":89367,"kind":"person","name":"USMAN NASSIM","position":1,"cik":"0001206872","reported_name":"USMAN NASSIM","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2019-02-04T21:51:45.000Z","date":"2019-01-31","kind":"exercise","acquired":false,"shares":5729,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The Option vests monthly over a period of four years commencing June 15, 2017"}],"balance_after":269271,"derivative":{"exercise_price":4.63,"expiration_date":"2027-07-11","underlying":"Common Stock","underlying_shares":5729},"source":{"system":"sec-edgar","filing":"0001209191-19-006857","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1124105/000120919119006857/doc4.xml","form_type":"4"}},{"id":3677848,"issuer":{"id":5247,"kind":"organization","name":"GYRE THERAPEUTICS, INC."},"owners":[{"id":89367,"kind":"person","name":"USMAN NASSIM","position":1,"cik":"0001206872","reported_name":"USMAN NASSIM","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2019-02-04T21:51:45.000Z","date":"2019-01-31","kind":"exercise","acquired":true,"shares":5729,"price":4.63,"value":26525.27,"ownership":{"direct":true},"balance_after":11041,"source":{"system":"sec-edgar","filing":"0001209191-19-006857","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1124105/000120919119006857/doc4.xml","form_type":"4"}},{"id":3685543,"issuer":{"id":5247,"kind":"organization","name":"GYRE THERAPEUTICS, INC."},"owners":[{"id":89367,"kind":"person","name":"USMAN NASSIM","position":1,"cik":"0001206872","reported_name":"USMAN NASSIM","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2019-01-28T23:58:12.000Z","date":"2019-01-24","kind":"grant","acquired":true,"shares":80000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Award vests over a four (4) year period on each monthly anniversary commencing January 24, 2019."}],"balance_after":80000,"derivative":{"exercise_price":7.97,"expiration_date":"2029-01-24","underlying":"Common Stock","underlying_shares":80000},"source":{"system":"sec-edgar","filing":"0001209191-19-005668","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1124105/000120919119005668/doc4.xml","form_type":"4"}},{"id":3857007,"issuer":{"id":5247,"kind":"organization","name":"GYRE THERAPEUTICS, INC."},"owners":[{"id":89367,"kind":"person","name":"USMAN NASSIM","position":1,"cik":"0001206872","reported_name":"USMAN NASSIM","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2018-08-01T21:48:39.000Z","date":"2018-07-30","kind":"grant","acquired":true,"shares":75000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Award vests monthly over four (4) years starting June 13, 2018."}],"balance_after":75000,"derivative":{"exercise_price":9.68,"expiration_date":"2028-07-30","underlying":"Common Stock","underlying_shares":75000},"source":{"system":"sec-edgar","filing":"0001209191-18-044791","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1124105/000120919118044791/doc4.xml","form_type":"4"}},{"id":3965580,"issuer":{"id":5247,"kind":"organization","name":"GYRE THERAPEUTICS, INC."},"owners":[{"id":89367,"kind":"person","name":"USMAN NASSIM","position":1,"cik":"0001206872","reported_name":"USMAN NASSIM","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2018-04-12T00:00:39.000Z","date":"2018-04-09","kind":"gift","acquired":true,"shares":88,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By The Usman Family Trust"},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Reflects a 1:15 reverse stock split effected on February 10, 2017."}],"balance_after":4144,"source":{"system":"sec-edgar","filing":"0001209191-18-024695","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1124105/000120919118024695/doc4.xml","form_type":"4"}},{"id":3965579,"issuer":{"id":5247,"kind":"organization","name":"GYRE THERAPEUTICS, INC."},"owners":[{"id":89367,"kind":"person","name":"USMAN NASSIM","position":1,"cik":"0001206872","reported_name":"USMAN NASSIM","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2018-04-12T00:00:39.000Z","date":"2018-04-09","kind":"gift","acquired":false,"shares":88,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":0,"source":{"system":"sec-edgar","filing":"0001209191-18-024695","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1124105/000120919118024695/doc4.xml","form_type":"4"}},{"id":3967790,"issuer":{"id":5247,"kind":"organization","name":"GYRE THERAPEUTICS, INC."},"owners":[{"id":89367,"kind":"person","name":"USMAN NASSIM","position":1,"cik":"0001206872","reported_name":"USMAN NASSIM","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2018-04-06T21:03:50.000Z","date":"2018-04-04","kind":"exercise","acquired":false,"shares":88,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The Option vests monthly over a period of four years commencing June 15, 2017."}],"balance_after":274912,"derivative":{"exercise_price":4.63,"expiration_date":"2027-07-11","underlying":"Common Stock","underlying_shares":88},"source":{"system":"sec-edgar","filing":"0001209191-18-024224","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1124105/000120919118024224/doc4.xml","form_type":"4"}},{"id":3967789,"issuer":{"id":5247,"kind":"organization","name":"GYRE THERAPEUTICS, INC."},"owners":[{"id":89367,"kind":"person","name":"USMAN NASSIM","position":1,"cik":"0001206872","reported_name":"USMAN NASSIM","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2018-04-06T21:03:50.000Z","date":"2018-04-04","kind":"exercise","acquired":true,"shares":88,"price":4.63,"value":407.44,"ownership":{"direct":true},"balance_after":88,"source":{"system":"sec-edgar","filing":"0001209191-18-024224","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1124105/000120919118024224/doc4.xml","form_type":"4"}},{"id":4099505,"issuer":{"id":5247,"kind":"organization","name":"GYRE THERAPEUTICS, INC."},"owners":[{"id":89367,"kind":"person","name":"USMAN NASSIM","position":1,"cik":"0001206872","reported_name":"USMAN NASSIM","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option(Right to Buy)","published_at":"2018-01-16T20:44:43.000Z","date":"2018-01-12","kind":"grant","acquired":true,"shares":95000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The Option vests monthly over a period of four years commencing January 12, 2018."}],"balance_after":95000,"derivative":{"exercise_price":15.13,"expiration_date":"2028-01-12","underlying":"Common Stock","underlying_shares":95000},"source":{"system":"sec-edgar","filing":"0000899243-18-001064","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1124105/000089924318001064/doc4.xml","form_type":"4"}},{"id":4258458,"issuer":{"id":5247,"kind":"organization","name":"GYRE THERAPEUTICS, INC."},"owners":[{"id":89367,"kind":"person","name":"USMAN NASSIM","position":1,"cik":"0001206872","reported_name":"USMAN NASSIM","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2017-07-12T20:45:07.000Z","date":"2017-07-11","kind":"grant","acquired":true,"shares":275000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The Option vests monthly over a period of four years commencing June 15, 2017."}],"balance_after":275000,"derivative":{"exercise_price":4.63,"expiration_date":"2027-07-11","underlying":"Common Stock","underlying_shares":275000},"source":{"system":"sec-edgar","filing":"0001209191-17-044899","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1124105/000120919117044899/doc4.xml","form_type":"4"}}]}